<DOC>
	<DOCNO>NCT01163097</DOCNO>
	<brief_summary>The purpose study evaluate effect continuous intravenous infusion unfractionated heparin multiple-dose pharmacodynamics palifermin healthy adult subject .</brief_summary>
	<brief_title>Study Characterize Effect Heparin Palifermin Activity</brief_title>
	<detailed_description>The plan study design characterize impact heparin biologic activity palifermin assess impact combination palifermin heparin tolerability . Approximately forty-three ( 43 ) eligible healthy adult men oophorectomized postmenopausal woman 18-45 year age assign one three treatment group treatment group A receive daily dose palifermin 40 µg/kg three consecutive day intravenous ( IV ) bolus injection continuous heparin IV infusion , treatment B receive daily dose palifermin 40 µg/kg three consecutive day IV bolus injection treatment C control group without treatment administer . The subject randomize 20:15:8 ratio ( Treatment A : B : C ) . The study consist 21-days screening period , 5-days treatment period 45-days follow-up period .</detailed_description>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Healthy men postmenopausal oophorectomized woman . Subjects Body Mass Index 19 30 inclusive . A negative screen drug abuse , tobacco use alcohol breath test . Subjects willing resident research facility 6 night return research facility schedule study followup procedure . Men must agree duration study use appropriate method birth control History evidence clinically significant disorder , condition disease would pose risk subject safety interfere study evaluation , procedure , completion . History evidence oral mucosal disease may affect mucosal keratinocyte proliferation . Evidence history thrombocytopenia , heparininduced thrombocytopenia contraindication heparin ( e.g . recent surgery ) . Known hypersensitivity heparin topical injectable local anesthetic . Known allergy Escherichia coliderived product allergy palifermin excipients . Use medication ( except vitamin , hormonal replacement therapy topical medication ) within 10 day admission research facility . Blood donation within 8 week prior dose investigational drug . History hypertension , clinically significant bleeding , gastrointestinal ulcer , arteriovenous malformation ( AVM ) , aneurysm , vascular malformation . History coagulopathy , bleed disorder abnormal platelet count . History malignancy type , surgically excise nonmelanoma skin cancer situ cervical cancer . For male , past history epididymitis . Known alcohol abuse use illicit drug within 12 month prior admission research facility . History smoke use smokeless tobacco within past year admission research facility . Any condition might reduce chance obtain data ( eg , know poor compliance ) require protocol might compromise ability give informed consent . Previous participation palifermin study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>